Anticoagulation in splanchnic and cerebral vein thrombosis: Still groping in the dark

Klok, Frederikus A.

doi:10.1002/rth2.12427

Cited by 1 publication

(1 citation statement)

References 8 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the limited and low‐quality available evidence on the use of the DOACs in this setting, some authors would still prefer traditional anticoagulant treatment for these patients 123 . However, RCTs in patients with unusual‐site VTE are difficult to conduct, mainly because of the rarity and the severity of these conditions.…”

Section: Discussionmentioning

confidence: 99%

Direct oral anticoagulants for unusual‐site venous thromboembolism

Riva

Ageno

2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Direct oral anticoagulants (DOACs) are currently the preferred oral anticoagulant treatment for most of the patients with deep vein thrombosis of the lower extremities and/or pulmonary embolism. DOACs have several advantages over vitamin K antagonists, such as availability of fixed dosages, fewer drug interactions, faster onset of action, shorter half‐life, and lower risk of major and intracranial bleeding. Although the evidence on the use of DOACs in patients with unusual‐site venous thromboembolism (VTE) is limited to a few, small randomized controlled trials, these drugs are increasingly used in clinical practice, and several observational cohort studies have been published recently. This narrative review will describe the latest evidence for the use of the DOACs in patients with thrombosis in atypical locations (splanchnic, cerebral, upper extremity, ovarian, and renal vein thrombosis) and will provide some practical advice for their use in patients with unusual‐site VTE.

show abstract

Section: Discussionmentioning

confidence: 99%